GLP-1 telehealth availability, state by state
As of November 20, 2026, no tracked program publishes state-specific prices: programs that serve a state charge their national prices. Availability depends on prescriber licensing and pharmacy permits; each state page lists published coverage, known exceptions and the national price tables.
Released · Last reviewed · how we verify
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
NexLife’s pages conflict on coverage: its FAQ lists 45 states and D.C. and excludes Alabama, Louisiana, Mississippi, Virginia and West Virginia, while its states page says all 50. Those five state pages do not list NexLife until it resolves the conflict.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)